Targeting Sporadic and Neurofibromatosis Type 1 (NF1) Related Refractory Malignant Peripheral Nerve Sheath Tumors (MPNST) in a Phase II Study of Everolimus in Combination with Bevacizumab (SARC016)

PURPOSE: There are no known effective medical treatments for refractory MPNST. Inactivation of the NF1 tumor suppressor in MPNST results in upregulation of mTOR (mammalian target of rapamycin) signaling and angiogenesis, which contributes to disease progression. We conducted a phase II study for pat...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
הוצא לאור ב:Sarcoma
Main Authors: Widemann, Brigitte C., Lu, Yao, Reinke, Denise, Okuno, Scott H., Meyer, Christian F., Cote, Gregory M., Chugh, Rashmi, Milhem, Mohammed M., Hirbe, Angela C., Kim, AeRang, Turpin, Brian, Pressey, Joseph G., Dombi, Eva, Jayaprakash, Nalini, Helman, Lee J., Onwudiwe, Ndidi, Cichowski, Karen, Perentesis, John P.
פורמט: Artigo
שפה:Inglês
יצא לאור: Hindawi 2019
נושאים:
Clinical Study
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC6681622/
https://ncbi.nlm.nih.gov/pubmed/31427883
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1155/2019/7656747
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים